DOI: 10.1055/s-00035024

Thrombosis and Haemostasis

References

Advani RH, Buggy JJ, Sharman JP. , et al.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

J Clin Oncol 2013;
31 (01) 88-94

Advani RH, Buggy JJ, Sharman JP. , et al.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

J Clin Oncol 2013;
31 (01) 88-94

Download Bibliographical Data

Search in: